In addition to the improvements derived from the 'Lessons learned' section above, the data from the survey raises potential areas for further research and changes in approach.
An interesting focus for future research could be the difference between Amitryptiline and Nortriptyline in terms of their side effects, symptomatic improvements and dosage. The difference in the reported benefits of these two drugs in the survey asks more questions than it answers. Only a more focussed study could address these questions.
Relying on the recollections of respondents about lifestyle factors, medications or supplements from a long time ago is problematic. Memory is fallible, and this approach does nothing to account for external factors that may have biased answers.
By using a longitudinal study format, respondents could be focussed to either maintaining a consistent routine, or varying factors deliberately, in order to get a clearer correlation between metrics over a period of days or weeks.
Future surveys should seek to authenticate users to ensure that participants meet study requirements, while also ensuring the privacy and anonymisation of released data.
By authenticating users, MalaDIO can secure a higher level of trust in responses, prevent duplicate responses, and provide the possibility of following-up on respondents for future research (with their consent) depending on their responses.
There are existing technological solutions that can offer this service and meet stringent ethical and legislative standards.